Alzheimer's trial brings at-risk patients hope for the future, but new doubts in the present

Could a new model of testing and drugs make this brain disease as treatable as Type 2 diabetes? As researchers run tests to find out, neuroscience is divided on what to do for now

Related Keywords

Toronto ,Ontario ,Canada ,Germany ,Ottawa ,Japan ,United States ,United Kingdom ,Amsterdam ,Noord Holland ,Netherlands ,China ,Canadians ,Americans ,German ,Canadian ,Britain ,American ,Sharon Cohen ,Whitney Haller ,Jason Karlawish ,Byravi Sivasubramaniam ,Lynn Zimmerman ,Suzanne Schindler ,Tyson Haller ,Andrew Frank ,John Mann ,Clifford Jack ,Jennifer Watt ,Eli Lilly ,Howard Chertkow ,Alois Alzheimer ,Health Canada ,Alzheimer Association ,American Geriatrics Society ,Canadian Consortium On Neurodegeneration ,Us Alzheimer Association ,University Of Pennsylvania ,Japan Eisai Co ,Toronto Memory Program ,Canadian Medical Association Journal ,U Biogen Inc ,Memory Program ,Penn Memory Center ,Washington University School Of Medicine ,Baycrest Health Sciences ,Log Increate Free ,Toronto Memory ,Canadian Consortium ,Washington University School ,Earlier Alzheimer ,Mayo Clinic ,Appwebview ,Aud Url ,Yesapplenews ,Aud Headline ,Alzheimer ,Disease ,Lecanemab ,People ,Drug ,Dementia ,Trial ,Decline ,St Michael X27s Hospital ,